Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. - Wikidata - wikimedia - TriplyDB

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

http://www.wikidata.org/entity/Q32040849

about

Radioisotopes for metastatic bone pain From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer Targeting bone physiology for the treatment of metastatic prostate cancer Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Samarium for osteoblastic bone metastases and osteosarcoma Radium-223 dichloride in clinical practice: a review.Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells.Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone Systemic radionuclide therapy in pain palliation.Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.WITHDRAWN: Radioisotopes for metastatic bone pain.A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.Bone-targeting agents in prostate cancer.NCCN Task Force Report: Bone Health in Cancer Care.Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.Pharmacological treatments for prostate cancer.Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.Targeted alpha-therapy for control of micrometastatic prostate cancer.Castration-resistant prostate cancer: systemic therapy in 2012 Osteoblasts in prostate cancer metastasis to bone.Radionuclide Therapy of Bone Metastases.Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.Overcoming drug resistance and treating advanced prostate cancer Novel agents and targets in managing patients with metastatic prostate cancer.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.New and emerging therapies for bone metastases in genitourinary cancers.Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.Optimal bone health management strategies in patients with prostate cancer Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer

P2860

Q24235589-53D889D0-741D-462A-911F-02357EF89E5C Q26740064-432D3A25-19A4-4BBF-9D8E-27968F63E5B8 Q26823733-29A09881-92CB-4F20-9537-80A42F1E0BBF Q26863249-BC392CCF-E647-4561-821B-3703BD39743E Q27024775-C2E91F57-403B-4544-AC13-14CC504BF6FC Q28079918-61A2AA16-B4C5-47A5-93AD-2131EC67917B Q28253337-1C721D10-0E0E-4EFA-8167-F74E758C8273 Q30251496-209D20D3-BC13-4CAE-8618-42C7E7F36E8D Q30308220-4B8A5EF4-DF39-4057-A8BC-BF17A5D44C42 Q30852837-8FCEE710-EE74-4FC6-83C6-31C6813B98BC Q33343008-B9766F46-D8FA-47F7-9E59-F726629A0BCA Q33369416-D09114AC-1C5E-4157-AD6E-A0F7553430BD Q33387322-5814BD4D-775D-4BD7-8A76-63409AEB7A8B Q33396382-2B0F3FDB-6D68-47DB-ACD3-BB74D2A348D3 Q33403308-FF718FEB-67BB-4D94-B4C7-B39003A3E40D Q33405335-7345B2E1-4C8B-42A2-8D00-5B037921FB4A Q33440341-93B5968D-19BE-49B2-9B0E-D603B0E8DFF2 Q33441119-B17A3201-3B43-4E05-A3F9-5EA4FECF6F55 Q33864723-5F6E51E1-C68C-40AB-B5FD-70FDC39221D9 Q34617936-97F80209-9B50-44BA-9B66-24332FB8C9DE Q34734425-BCBF1D49-8FF6-4D13-BF1F-2CEB0B8DC0C6 Q35011889-3B630D6E-7C57-426C-98C6-ED26FA4F72C0 Q35083825-297D1940-6A88-40C7-AA70-C5DD1AE6FFC5 Q35143943-4EE9147B-694C-40C5-B1E9-06B03ACF6908 Q35147059-F7779DAF-921A-47D1-9263-D3967088FA76 Q35490140-183B186C-ABCA-467D-9B87-4DAAACE5FE1F Q35782949-4CF1D09F-4651-4334-945C-1B2765622857 Q35865011-BF62CE6D-B510-494E-AE50-DDB17A85A922 Q35998759-F4E706E7-4595-4988-A495-C55B34E20F88 Q36036136-6B028FD3-064E-42E7-9F0B-3BBE723B7247 Q36224128-8E6D8F9F-6956-476E-AEA1-138DC95DCFF2 Q36328812-C97CD233-A24A-4128-AFEE-FF95DE63F484 Q36555662-BF9E1169-F027-42EB-A51D-27447FC852BF Q36840731-E92E5BAB-B8B7-417B-B39E-6C408A6499D7 Q36866291-336AEA5F-CCCA-4ECF-B65F-572ACBD9F0AD Q37004657-92A99A47-0819-4A56-8BA0-F95AAD82B382 Q37080734-375A69C1-67E7-4F76-A42F-6A5A1F87B88F Q37107575-BF0A3DF5-82A5-41AD-B05C-F4D65C613D1E Q37166534-6B93CFC1-CD2C-415C-BE44-BBE7431C5362 Q37193613-4E97BDCF-08BA-4C62-B739-06CDFDA8E2D6

P2860

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

http://www.wikidata.org/entity/Q32040849

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@ast

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@en

type

label

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@ast

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@en

prefLabel

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@ast

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@en

P1433

Q32040849-831B1232-552C-4BA3-8F69-C02E15AFE7C2

P1476

Q32040849-07C19839-1081-4274-900C-487EFC4E98E9

P2093

Q32040849-19905AEA-1BB8-4D85-832C-86F4741CE506

Q32040849-36C2DEF4-99CD-41F7-9871-D17BFDF18C10

Q32040849-3AF36E53-8BC8-45B3-8315-8DFDC8380583

Q32040849-43A455D6-6CD5-4086-9EF3-CD346A6D2B18

Q32040849-66CB80AD-CE2A-4469-8608-57F5EADD2BB5

Q32040849-77D5C71F-BFA3-4DF1-958E-5000627290EE

Q32040849-8763CF77-6AD0-41BA-9BAD-0B9B653EAD48

Q32040849-AB866D3C-198F-484A-B78B-7301D2A5A814

Q32040849-ADCE05FB-CD45-4DC3-A2F1-76E2E8CFD916

Q32040849-DA68105D-7647-4F88-A0E1-1ECF435425AB

P304

Q32040849-808FA92D-E9A1-4C7A-9AC2-BF64950E5096

P31

Q32040849-70F002C1-14A7-4536-89B1-50A5AFAACE04

P356

Q32040849-F6C66320-4919-4F78-874F-5C9344CF853E

P407

Q32040849-7F568E7F-4509-471C-A1E2-28FCE7DA1559

P433

Q32040849-62B2E7A3-51C5-464B-A5DB-3A138E36F554

P478

Q32040849-E2E44FD7-EDE1-49A1-B955-2EEEE405FA11

P577

Q32040849-609C29A5-2B2D-4A59-BEFA-83D478708479

P698

Q32040849-2340FE78-18B2-45B5-8746-91E8A17A81EE

P921

Q32040849-F812F95A-21E5-4D75-B9A6-3EC31D0D7743

P356

S0140-6736(00)03639-4

P1433

P1476

Bone-targeted therapy for adva ...... : a randomised phase II trial.

@en

P2093

B Mengistu

http://www.w3.org/2001/XMLSchema#string

C J Logothetis

http://www.w3.org/2001/XMLSchema#string

C N Papandreou

http://www.w3.org/2001/XMLSchema#string

D A Podoloff

http://www.w3.org/2001/XMLSchema#string

D Daliani

http://www.w3.org/2001/XMLSchema#string

E S Delpassand

http://www.w3.org/2001/XMLSchema#string

J Kim

http://www.w3.org/2001/XMLSchema#string

L C Pagliaro

http://www.w3.org/2001/XMLSchema#string

R E Millikan

http://www.w3.org/2001/XMLSchema#string

R J Amato

http://www.w3.org/2001/XMLSchema#string

P304

336-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(00)03639-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

9253

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11210994

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial